What to Look for in COPD Next Year

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.

The Prescription Drug User Fee Act date is set for May 7, 2025.

The 2 newly approved COPD therapies have been added to the GOLD guidelines section on follow-up therapy, expanding clinical options for specific patient types.

Your daily dose of the clinical news you may have missed.